Additional file 3: of Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38

Additional file 3: of Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer

Ricardo Ribas (222948)
Sunil Pancholi (222942)
Aradhana Rani (529007)
Eugene Schuster (12754)
Stephanie Guest (5350772)
Joanna Nikitorowicz-Buniak (776212)
Nikiana Simigdala (424363)
Allan Thornhill (5350766)
Francesca Avogadri-Connors (5350769)
Richard Cutler (5350763)
Alshad Lalani (5350775)
Mitch Dowsett (645)
Stephen Johnston (767275)
Lesley-Ann Martin (222958)

June 2018

Figure S3. Anti-proliferative effect of neratinib in combination with endocrine agents (a) 4-OHT and...

Additional file 1: of Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings

Astrid Leech (5997860)
Sri HariKrishna Vellanki (5997863)
Emily Rutherford (5997872)
Aoife Keogh (5997878)
Hanne Jahns (5997881)
Lance Hudson (5997884)
Norma OâDonovan (4283089)
Siham Sabri (450448)
Bassam Abdulkarim (450452)
Katherine Sheehan (4283038)
Elaine Kay (414758)
Leonie Young (3565385)
Arnold Hill (3565382)
Yvonne Smith (5997887)
Ann Hopkins (5997890)

November 2018

Lapatinib treatment significantly reduces viability of SK-BR-3âsensitive but not SK-BR-3 lapatinib...

Additional file 3: of Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer

Natalia Arango (4358398)
Erkan Yuca (4358395)
Ming Zhao (48501)
Kurt Evans (4358407)
Stephen Scott (2822591)
Charissa Kim (4358401)
Ana Gonzalez-Angulo (4358404)
Filip Janku (160679)
Naoto Ueno (85718)
Debu Tripathy (417683)
Argun Akcakanat (790676)
Aung Naing (160702)
Funda Meric-Bernstam (478258)

August 2017

Effects of selinexor on the cell cycle. SUM-159PT and MDA-MB-468 cells were treated with 1 nM paclit...

Additional file 7: of Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38

Katharina Gohr (4571839)
Alexandra Hamacher (534446)
Laura Engelke (1867372)
Matthias Kassack (2160217)

November 2017

Characterization of MDA-MB231 and cisplatin-resistant MDA-MB231CisR. MDA-MB231 and cisplatin-resista...

Additional file 1: of The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells

Daniele Cretella (475207)
Andrea Ravelli (5022788)
Claudia Fumarola (475204)
Silvia La Monica (475199)
Graziana Digiacomo (5022785)
Andrea Cavazzoni (475206)
Roberta Alfieri (79926)
Alessandra Biondi (5022779)
Daniele Generali (426339)
Mara Bonelli (475205)
Pier Petronini (5022782)

March 2018

Table S1. Sensitivity of TNBC cells to PI3K/mTOR inhibitors. HCC38 cells and MDA-MB-231 cells were t...

Additional file 3: Figure S2. of Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-κB-TNFα-PIK3CA loop

Bhushan Thakur (4614046)
Pritha Ray (279482)

November 2017

NF-κB escalated PIK3CA promoter activity in SP cells. Cisplatin and TNFα but not lithium chloride or...

Additional file 1: Table S1. of Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-κB-TNFα-PIK3CA loop

Bhushan Thakur (4614046)
Pritha Ray (279482)

November 2017

List of protein identified exclusively in A2780-CisR control (untreated) cells. Table S2. List of pr...

Additional file 3: of A tight balance of Karyopherin β1 expression is required in cervical cancer cells

Sarah Carden (5984072)
Pauline van der Watt (5984078)
Alicia Chi (5984081)
Aderonke Ajayi-Smith (5984084)
Katie Hadley (5984087)
Virna Leaner (5984090)

November 2018

Figure S3. p53 and p21 inhibition reduces and enhances CaSki EGFP and Kpnβ1-EGFP cell sensitivity to...

Additional file 3: of Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer

Nuramalina Mumin (6262541)
Neele Drobnitzky (6262547)
Agata Patel (6262553)
Luiza Lourenco (6262556)
Fiona Cahill (6262562)
Yanyan Jiang (253354)
Anthony Kong (94738)
Anderson Ryan (482874)

January 2019

Table S2. Compounds that were selectively cytotoxic to parental Hs578T cells compared with HSP90i-re...

Additional file 3: of DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines

Hogir Salim (3547547)
Dali Zong (3547541)
Petra Hååg (3547544)
Metka Novak (706791)
Birgitta Mörk (3547553)
Rolf Lewensohn (809379)
Lovisa Lundholm (3547550)
Kristina Viktorsson (2203072)

September 2015

A549 cells were transfected with non-targeting (NT) or DKK1-specific siRNA (si1). (A) Silencing of D...

Additional file 5: Figure S4. of Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-κB-TNFα-PIK3CA loop

Bhushan Thakur (4614046)
Pritha Ray (279482)

November 2017

Cisplatin induced NF-κB and its physical interaction with PIK3CA promoter in TOV21G and SKOV3 cells....

Additional file 5: of Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin

Chao He (466651)
Jian Sun (27858)
Chao Liu (43092)
Yuhang Jiang (2344720)
Yongqiang Hao (387139)

January 2019

Figure S5. Overexpression of PRKCA reverses the chemosensitization effects of GSK-J4 with regards to...

Additional file 3: of Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

Alex Eustace (5515580)
Neil Conlon (4012034)
Martina McDermott (5844752)
Brigid Browne (5844755)
Patrick O’Leary (2112757)
Frankie Holmes (5844758)
Virginia Espina (209337)
Lance Liotta (238260)
Joyce O’Shaughnessy (5844761)
Clair Gallagher (419255)
Lorraine O’Driscoll (112362)
Sweta Rani (112339)
Stephen Madden (2611069)
Neil O’Brien (5844764)
Charles Ginther (5844767)
Dennis Slamon (70141)
Naomi Walsh (5844770)
William Gallagher (4283029)
Radoslaw Zagozdzon (5844773)
William Watson (112355)
Norma O’Donovan (2074084)
John Crown (112358)

October 2018

Figure S3. TRAIL expression in SKBR3-Par and SKBR3-L cells. A) TRAIL 1 and TRAIL 2 receptor expressi...

Additional file 3: of Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation

An-Yue Wu (6636974)
Li-Ying Gu (6636977)
Wei Cang (6636980)
Meng-Xing Cheng (6636983)
Wen-Jing Wang (769627)
Wen Di (384960)
Lei Huang (35191)
Li-Hua Qiu (6636986)

April 2019

Figure S3. Fn14 inhibits cisplatin resistance in HGSOC primary cancer cells with p53-R248Q. (A)-(D) ...

Additional file 3: of Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin

Chao He (466651)
Jian Sun (27858)
Chao Liu (43092)
Yuhang Jiang (2344720)
Yongqiang Hao (387139)

January 2019

Figure S3. Knockdown of KDM6A or KDM6B enhances cisplatin-induced apoptosis in OS cells. Cleaved Cas...

Additional file 3: of Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer

Ricardo Ribas (222948)
Sunil Pancholi (222942)
Aradhana Rani (529007)
Eugene Schuster (12754)
Stephanie Guest (5350772)
Joanna Nikitorowicz-Buniak (776212)
Nikiana Simigdala (424363)
Allan Thornhill (5350766)
Francesca Avogadri-Connors (5350769)
Richard Cutler (5350763)
Alshad Lalani (5350775)
Mitch Dowsett (645)
Stephen Johnston (767275)
Lesley-Ann Martin (222958)

June 2018

Figure S3. Anti-proliferative effect of neratinib in combination with endocrine agents (a) 4-OHT and...

Additional file 1: of Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings

Astrid Leech (5997860)
Sri HariKrishna Vellanki (5997863)
Emily Rutherford (5997872)
Aoife Keogh (5997878)
Hanne Jahns (5997881)
Lance Hudson (5997884)
Norma OâDonovan (4283089)
Siham Sabri (450448)
Bassam Abdulkarim (450452)
Katherine Sheehan (4283038)
Elaine Kay (414758)
Leonie Young (3565385)
Arnold Hill (3565382)
Yvonne Smith (5997887)
Ann Hopkins (5997890)

November 2018

Lapatinib treatment significantly reduces viability of SK-BR-3âsensitive but not SK-BR-3 lapatinib...

Additional file 3: of Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer

Natalia Arango (4358398)
Erkan Yuca (4358395)
Ming Zhao (48501)
Kurt Evans (4358407)
Stephen Scott (2822591)
Charissa Kim (4358401)
Ana Gonzalez-Angulo (4358404)
Filip Janku (160679)
Naoto Ueno (85718)
Debu Tripathy (417683)
Argun Akcakanat (790676)
Aung Naing (160702)
Funda Meric-Bernstam (478258)

August 2017

Effects of selinexor on the cell cycle. SUM-159PT and MDA-MB-468 cells were treated with 1 nM paclit...

Additional file 7: of Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38

Katharina Gohr (4571839)
Alexandra Hamacher (534446)
Laura Engelke (1867372)
Matthias Kassack (2160217)

November 2017

Characterization of MDA-MB231 and cisplatin-resistant MDA-MB231CisR. MDA-MB231 and cisplatin-resista...

Additional file 1: of The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells

Daniele Cretella (475207)
Andrea Ravelli (5022788)
Claudia Fumarola (475204)
Silvia La Monica (475199)
Graziana Digiacomo (5022785)
Andrea Cavazzoni (475206)
Roberta Alfieri (79926)
Alessandra Biondi (5022779)
Daniele Generali (426339)
Mara Bonelli (475205)
Pier Petronini (5022782)

March 2018

Table S1. Sensitivity of TNBC cells to PI3K/mTOR inhibitors. HCC38 cells and MDA-MB-231 cells were t...

Additional file 3: Figure S2. of Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-κB-TNFα-PIK3CA loop

Bhushan Thakur (4614046)
Pritha Ray (279482)

November 2017

NF-κB escalated PIK3CA promoter activity in SP cells. Cisplatin and TNFα but not lithium chloride or...

Additional file 1: Table S1. of Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-κB-TNFα-PIK3CA loop

Bhushan Thakur (4614046)
Pritha Ray (279482)

November 2017

List of protein identified exclusively in A2780-CisR control (untreated) cells. Table S2. List of pr...

Additional file 3: of A tight balance of Karyopherin β1 expression is required in cervical cancer cells

Sarah Carden (5984072)
Pauline van der Watt (5984078)
Alicia Chi (5984081)
Aderonke Ajayi-Smith (5984084)
Katie Hadley (5984087)
Virna Leaner (5984090)

November 2018

Figure S3. p53 and p21 inhibition reduces and enhances CaSki EGFP and Kpnβ1-EGFP cell sensitivity to...

Additional file 3: of Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer

Nuramalina Mumin (6262541)
Neele Drobnitzky (6262547)
Agata Patel (6262553)
Luiza Lourenco (6262556)
Fiona Cahill (6262562)
Yanyan Jiang (253354)
Anthony Kong (94738)
Anderson Ryan (482874)

January 2019

Table S2. Compounds that were selectively cytotoxic to parental Hs578T cells compared with HSP90i-re...

Additional file 3: of DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines

Hogir Salim (3547547)
Dali Zong (3547541)
Petra Hååg (3547544)
Metka Novak (706791)
Birgitta Mörk (3547553)
Rolf Lewensohn (809379)
Lovisa Lundholm (3547550)
Kristina Viktorsson (2203072)

September 2015

A549 cells were transfected with non-targeting (NT) or DKK1-specific siRNA (si1). (A) Silencing of D...

Additional file 5: Figure S4. of Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-κB-TNFα-PIK3CA loop

Bhushan Thakur (4614046)
Pritha Ray (279482)

November 2017

Cisplatin induced NF-κB and its physical interaction with PIK3CA promoter in TOV21G and SKOV3 cells....

Additional file 5: of Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin

Chao He (466651)
Jian Sun (27858)
Chao Liu (43092)
Yuhang Jiang (2344720)
Yongqiang Hao (387139)

January 2019

Figure S5. Overexpression of PRKCA reverses the chemosensitization effects of GSK-J4 with regards to...

Additional file 3: of Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

Alex Eustace (5515580)
Neil Conlon (4012034)
Martina McDermott (5844752)
Brigid Browne (5844755)
Patrick O’Leary (2112757)
Frankie Holmes (5844758)
Virginia Espina (209337)
Lance Liotta (238260)
Joyce O’Shaughnessy (5844761)
Clair Gallagher (419255)
Lorraine O’Driscoll (112362)
Sweta Rani (112339)
Stephen Madden (2611069)
Neil O’Brien (5844764)
Charles Ginther (5844767)
Dennis Slamon (70141)
Naomi Walsh (5844770)
William Gallagher (4283029)
Radoslaw Zagozdzon (5844773)
William Watson (112355)
Norma O’Donovan (2074084)
John Crown (112358)

October 2018

Figure S3. TRAIL expression in SKBR3-Par and SKBR3-L cells. A) TRAIL 1 and TRAIL 2 receptor expressi...

Additional file 3: of Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation

An-Yue Wu (6636974)
Li-Ying Gu (6636977)
Wei Cang (6636980)
Meng-Xing Cheng (6636983)
Wen-Jing Wang (769627)
Wen Di (384960)
Lei Huang (35191)
Li-Hua Qiu (6636986)

April 2019

Figure S3. Fn14 inhibits cisplatin resistance in HGSOC primary cancer cells with p53-R248Q. (A)-(D) ...

Additional file 3: of Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin

Chao He (466651)
Jian Sun (27858)
Chao Liu (43092)
Yuhang Jiang (2344720)
Yongqiang Hao (387139)

January 2019

Figure S3. Knockdown of KDM6A or KDM6B enhances cisplatin-induced apoptosis in OS cells. Cleaved Cas...

Additional file 3: of Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer

Ricardo Ribas (222948)
Sunil Pancholi (222942)
Aradhana Rani (529007)
Eugene Schuster (12754)
Stephanie Guest (5350772)
Joanna Nikitorowicz-Buniak (776212)
Nikiana Simigdala (424363)
Allan Thornhill (5350766)
Francesca Avogadri-Connors (5350769)
Richard Cutler (5350763)
Alshad Lalani (5350775)
Mitch Dowsett (645)
Stephen Johnston (767275)
Lesley-Ann Martin (222958)

June 2018

Figure S3. Anti-proliferative effect of neratinib in combination with endocrine agents (a) 4-OHT and...

Additional file 1: of Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings

Astrid Leech (5997860)
Sri HariKrishna Vellanki (5997863)
Emily Rutherford (5997872)
Aoife Keogh (5997878)
Hanne Jahns (5997881)
Lance Hudson (5997884)
Norma OâDonovan (4283089)
Siham Sabri (450448)
Bassam Abdulkarim (450452)
Katherine Sheehan (4283038)
Elaine Kay (414758)
Leonie Young (3565385)
Arnold Hill (3565382)
Yvonne Smith (5997887)
Ann Hopkins (5997890)

November 2018

Lapatinib treatment significantly reduces viability of SK-BR-3âsensitive but not SK-BR-3 lapatinib...

Additional file 3: of Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer

Natalia Arango (4358398)
Erkan Yuca (4358395)
Ming Zhao (48501)
Kurt Evans (4358407)
Stephen Scott (2822591)
Charissa Kim (4358401)
Ana Gonzalez-Angulo (4358404)
Filip Janku (160679)
Naoto Ueno (85718)
Debu Tripathy (417683)
Argun Akcakanat (790676)
Aung Naing (160702)
Funda Meric-Bernstam (478258)

August 2017

Effects of selinexor on the cell cycle. SUM-159PT and MDA-MB-468 cells were treated with 1 nM paclit...

Additional file 3: of Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38

Abstract

Extracted data

Additional file 3: of Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38

Abstract

Extracted data

Related items

Related items